
Dr Ruth Pidsley
Dr Ruth Pidsley is an NHMRC Investigator Fellow, Group Leader of the DNA Methylation Biomarkers group at the Garvan Institute of Medical Research and Conjoint Lecturer at St Vincent's Clinical School, UNSW Sydney. She graduated with a degree in Human Sciences from Oxford University, before studying for an MSc/PhD at King's College London, investigating epigenetics in the human brain and neuropsychiatric disorders. In 2013 she transitioned to cancer research, joining Professor Susan Clark’s Epigenetics Research Lab at Garvan, and established her own research group in 2018.
The research in Ruth's group focuses primarily on the role of epigenetics in the prostate tumour microenvironment. Their goal is to use this epigenetic information to improve cancer diagnosis and prognosis, so that patients can receive the correct treatment.
Since starting her scientific career in 2007, Ruth has published more than 35 papers, she has co-supervised the research projects of MSc and undergraduate students, as well as lecturing on two MSc courses. She has been awarded competitive funding for research projects from CINSW, CCNSW and NHMRC. She has contributed to further improving the research environment through serving on Garvan’s Postdoctoral Development and Engagement Committees and the NSW Australian Society for Medical Research (ASMR) Committee. Ruth also engages with patient consumers to guide her research and shares her research outcomes with the general public through public events at Garvan.
Awards
- 2022
NHMRC Investigator Fellowship
- 2015
Cancer Institute New South Wales Early Career Fellowship
- 2013
Gottesman-Shields Award for best PhD at the MRC SGDP Department - King’s College London - UK
- 2012
Tadion Rideal Prize for best PhD across the biomedical sciences at King’s College London - UK
- 2008
MRC Studentship for MSc/PhD course at the MRC SGDP Department - King’s College London - UK
Selected publications
See all publications- PUBLISHED 27 January 2026Clinical Epigenetics
DNA methylation estimates of immune cell abundance have prognostic potential in triple negative breast cancer
- PUBLISHED 21 August 2025Epigenomics
DNA methylation biomarkers for the diagnosis and treatment management of breast cancer: where are we now?
- PUBLISHED 30 October 2024BJUI Compass
Investigating the prognostic utility of promoter methylation in prostate cancer
- PUBLISHED 6 March 2024BMC Genomics
Characterisation and reproducibility of the HumanMethylationEPIC v2.0 BeadChip for DNA methylation profiling
- PUBLISHED 1 February 2024The Journal of Pathology
Detailed DNA methylation characterisation of phyllodes tumours identifies a signature of malignancy and distinguishes phyllodes from metaplastic breast carcinoma
